.jpg)
Aravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
May 28, 2019, Melbourne, Victoria – Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy Aravax, a...
May 29, 2019
Australian peanut therapy developer Aravax reveals positive Phase I trial results at AAAAI
February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical...
Feb 25, 2019
Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...
Feb 13, 2019
Aravax receives $1.9 million investment tranche from the Medical Research Commercialisation Fund
2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research...
May 2, 2018
Collaborator of Aravax, the Benaroya Research Institute, receives $5 million grant
29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute...
Jan 29, 2018
Aravax presents encouraging preliminary Phase I safety data at the first Gordon Research Conference
13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the...
Jan 13, 2018